2024/05/10 Medigen Announces Successful Implementation of TGA GMP Standards

Taipei, Taiwan, May 10, 2024 – Medigen, is proud to announce the successful implementation of the Therapeutic Goods Administration (TGA) Good Manufacturing Practice (GMP) standards across its facilities for COVID-19. This strategic move is part of Medigen's commitment to meeting stringent global regulatory requirements and delivering high-quality vaccines.


As of May 10, 2024, Medigen's manufacturing facilities have been certified to align with TGA GMP regulations, reflecting our dedication to maintaining the highest standards in vaccine production. This is especially significant for future pandemic preparedness, as it strengthens Medigen’s capability to support global health with efficacious and safe vaccines.


Our adherence to TGA GMP standards ensures that all processes and products meet rigorous quality controls. Medigen is committed to excellence and continuous improvement in our operations to ensure the safety and efficacy of our products.


This certification is an important step forward for Medigen as we continue to expand our presence in international markets and contribute to the global fight against infectious diseases.

We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies. Our Privacy & Cookie Policy contains more information on such use and explains how to disable cookies.